Novartis Sues FDA to Prevent Marketing of Entresto Generic

Immediately after the FDA rejected Novartis’s 2022 citizen petition for the agency to refrain from approving generic versions of its cardiac drug Entresto (sacubitril and valsartan), the company has filed a lawsuit against the FDA for approval of a generic version.
Source: Drug Industry Daily